TY - JOUR
KW - extended-release injectable suspension naltrexone
KW - oral naltrexone
KW - Behavioral Therapy
KW - opioid use disorder
KW - combined treatment
KW - treatment retention
KW - Empirical Study
KW - Quantitative Study
KW - Treatment Outcome
KW - Human
KW - Male
KW - Female
KW - Outpatient
KW - Adulthood (18 yrs & older)
KW - Young Adulthood (18-29 yrs)
KW - Thirties (30-39 yrs)
KW - Middle Age (40-64 yrs)
KW - Behavior Therapy
KW - Treatment Outcomes
KW - Drug Therapy
KW - Drug Administration Methods
KW - Naltrexone
KW - Substance use treatment
KW - article
KW - US
KW - 3383:Drug & Alcohol Rehabilitation
AU - Maria A. Sullivan
AU - Adam Bisaga
AU - Martina Pavlicova
AU - Kenneth M. Carpenter
AU - C. J. Choi
AU - Kaitlyn Mishlen
AU - Frances R. Levin
AU - John J. Mariani
AU - Edward V. Nunes
A1 - 
AD - Division on Substance Use, Department of Psychiatry, Columbia University, New York, NY, US mas23@cumc.columbia.edu; Sullivan, Maria A.,mas23@cumc.columbia.edu
BT - The American Journal of Psychiatry
C5 - Opioids & Substance Use
CP - 2
DO - 10.1176/appi.ajp.2018.17070732
IS - 2
JF - The American Journal of Psychiatry
LA - English
M1 - Journal Article
PB - American Psychiatric Assn
PY - 2019
SN - 0002-953X, 0002-953X
SP - 129
EP - 137
EP - 
T1 - A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder
T2 - The American Journal of Psychiatry
TI - A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder
U1 - Opioids & Substance Use
U3 - 10.1176/appi.ajp.2018.17070732
VL - 176
VO - 0002-953X, 0002-953X
Y1 - 2019
Y2 - Feb 01
ER -